Daratumumab treatment increases the risk of upper respiratory tract infections in multiple myeloma : A systematic review and meta-analysis

Abstract: Purpose This systematic review and meta-analysis was conducted to investigate the risk of upper respiratory tract infection in multiple myeloma patients undergoing antineoplastic therapy with the anti-CD38 monoclonal antibody Daratumumab. Methods PubMed, CINAHL, and Scopus databases were searched for publications describing rate of upper respiratory tract infections in multiple myeloma patients treated with Daratumumab. Covidence.org was used as a framework to conduct the evidence synthesis, the statistical calculations were performed in RStudio. Results Patients receiving Daratumumab to treat multiple myeloma are 1.63 times more likely to suffer from upper respiratory tract infections. Conclusion Daratumumab significantly increases the risk of upper respiratory tract infections in multiple myeloma patients. Healthcare providers should be aware of this risk and take appropriate measures to protect and educate multiple myeloma patients undergoing Daratumumab treatment.